share_log

Connect Biopharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Zheng Wei(11.7%)

SEC announcement ·  Feb 13 16:29
Summary by Moomoo AI
On December 31, 2023, Zheng Wei, a United States citizen, filed an amended Schedule 13G/A with the Securities and Exchange Commission, disclosing a significant stake in Connect Biopharma Holdings Limited. The filing indicates that Zheng Wei holds beneficial ownership of 6,487,545 ordinary shares of Connect Biopharma, representing 11.7% of the company. This ownership includes 5,928,164 ordinary shares and 559,381 shares underlying stock options exercisable as of March 1, 2024. The filing was made pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934. Connect Biopharma, with its principal executive offices located in San Diego, California, trades its ordinary shares in the form of American Depositary Shares (ADSs), each representing one ordinary share, under the CUSIP number 207523101.
On December 31, 2023, Zheng Wei, a United States citizen, filed an amended Schedule 13G/A with the Securities and Exchange Commission, disclosing a significant stake in Connect Biopharma Holdings Limited. The filing indicates that Zheng Wei holds beneficial ownership of 6,487,545 ordinary shares of Connect Biopharma, representing 11.7% of the company. This ownership includes 5,928,164 ordinary shares and 559,381 shares underlying stock options exercisable as of March 1, 2024. The filing was made pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934. Connect Biopharma, with its principal executive offices located in San Diego, California, trades its ordinary shares in the form of American Depositary Shares (ADSs), each representing one ordinary share, under the CUSIP number 207523101.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more